New Amsterdam Sciences is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. NAS911B is the company's lead compound, and is being pursued for indications including idiopathic pulmonary fibrosis, influenza infection, wound healing and solid tumors. New Amsterdam Sciences is devoted to developing products for both the commercial market and government markets, with exceptional candidates for mass-casualty biodefense applications specifically addressing acute radiation sickness (neutropenia), chemical exposure and biological warfare scenarios. To complete this mission, the company has cultivated numerous study partnerships with industry and academic leaders, including the Vaccine and Gene Therapy Institute of Florida, the University of Rochester, Harvard School of Medicine, and more. For additional information, please visit www.newamsterdamsciences.com
Company Details
- Employees
- 3
- Founded
- 2013
- Phone
- 480.477.7735
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- newamsterdamsciences.com
New Amsterdam Sciences, Inc Questions
New Amsterdam Sciences, Inc's helpline number is 480.477.7735
New Amsterdam Sciences, Inc's website is newamsterdamsciences.com
New Amsterdam Sciences, Inc's LinkedIn profile is https://www.linkedin.com/company/new-amsterdam-sciences-inc
New Amsterdam Sciences, Inc has
3 employees.
View email and phone details for 3
employees at New Amsterdam Sciences, Inc.
New Amsterdam Sciences, Inc's industry is
Biotechnology Research
New Amsterdam Sciences, Inc's top competitors are
Acute-Ai Amsterdam Umc,
Akigai,
Amsterdam Vesicle Center,
Oncotherics,
Savara Inc.,
Amsterdam Pharmacy,
New Amsterdam Genomics,
Elevatebio,
Newamsterdam Pharma Corporation,
Igem Amsterdam 2020 "forbidden Fruits".
New Amsterdam Sciences, Inc's categories are Biotechnology Research
New Amsterdam Sciences, Inc's founding year is 2013
